Blog
From StemRNA™ Clinical Seed Clone to GMP-Ready Cell Therapy Programs
Discover how REPROCELL’s StemRNA™ Clinical iPSC Seed Clones streamline the path to GMP-ready cell therapy, simplifying regulatory processes and enabling scalable, high-quality manufacturing.
27 February 2026
Preserving the Microenvironment-Advances in Ex Vivo Colonic Tissue Culture for IBD Drug Discovery
Advances in ex vivo colonic tissue culture preserve the microenvironment, enhancing IBD drug discovery by maintaining native tissue architecture and immune complexity for more predictive research models.
26 February 2026
Integrating AI with Ex Vivo Data: How Machine Learning Is Enhancing Predictive Accuracy in Human Tissue Studies
Discover how integrating AI with ex vivo human tissue data is revolutionizing drug discovery by enhancing predictive accuracy and bridging the gap between preclinical and clinical research.
12 February 2026
The Critical Role of Central Laboratory Services in Regulatory Compliance and Data Integrity
Explore the critical role of Central Laboratory Services in ensuring data integrity and regulatory compliance in drug development. Learn how CLS supports reliable, reproducible, and auditable data.
27 January 2026
Upcoming Events
Conferences we will be attending, and webinars hosted by us
Corporate News
28 January 2026
07 November 2025
REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)
22 October 2025
Investor Relations News